Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cloudflare Inc (NET) vs Viatris Inc (VTRS) Price & Performance

Cloudflare IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Cloudflare Inc vs Viatris Inc — how do they compare? Cloudflare Inc trades at $346.5 (market cap $121.74B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Cloudflare Inc is far larger — about 6.1× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cloudflare Inc for 61 Days and Viatris Inc for 57 Days on average.

NETVTRS
Market Cap
$121.74B$20.03B
Volume
2,433,00214,109,977
Sector
TechnologyHealth
52-Week High
$359.60$18.27
52-Week Low
$160.16$9.74
Typical Hold Time
61 Days57 Days
Enterprise Value
$121.11B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cloudflare Inc

Cloudflare (NET) trades at $342.82, down 3.44% on the day, as the stock consolidates near recent highs. The company continues to demonstrate strong revenue growth with $2.17 billion in 2025 sales, though profitability remains challenged with a -8.21% net margin. Recent technical indicators show a bullish trend with the stock trading above key support levels, while analyst sentiment remains overwhelmingly positive with 71% buy ratings. The company's recent product launches including Cloudflare Basin and strategic partnerships with Deutsche Telekom highlight ongoing innovation in the connectivity cloud space.

Cloudflare presents a growth story with expanding enterprise adoption but faces valuation concerns at current levels. The stock's premium multiples (P/S 47.88) require continued execution against strong revenue growth targets. Key risks include persistent profitability challenges and competitive pressures in the cloud security market, while catalysts include AI-driven security demand and platform consolidation opportunities.

Viatris Inc

Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.

Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NET
61% Buy39% Sell
Avg holding period · 61 Days
VTRS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Cloudflare Inc

Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.

Read more on NET →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →